DGAP-News: Prothena Announces Research and Development Day and Webcast
(firmenpresse) - Prothena Corporation
28.10.2013 14:06
---------------------------------------------------------------------------
DUBLIN, Ireland, 2013-10-28 14:06 CET (GLOBE NEWSWIRE) --
Prothena Corporation plc (Nasdaq:PRTA), a clinical stage biotechnology company
focused on the discovery, development and commercialization of novel antibodies
for the potential treatment of a broad range of diseases, today announced that
it will host its Research and Development Day on Monday, November 4, 2013 from
9:00 a.m - 12:00 p.m. ET at the New York Palace Hotel in New York, NY.
A live webcast of the conference can be accessed through the investor relations
section of the Company's website at www.prothena.com. Following the live
presentation, a replay of the webcast will be available on the Company's
website for 90 days.
Prothena management and scientists will discuss the Company's progress on its
lead programs:
-- NEOD001, a monoclonal antibody targeting AL and AA amyloid for the
potential treatment of amyloidosis
-- PRX002, a monoclonal antibody targeting alpha-synuclein for the potential
treatment of Parkinson's disease
-- PRX003, a monoclonal antibody targeting MCAM (melanoma cell adhesion
molecule) for the potential treatment of inflammatory diseases and cancers
Independent subject matter experts will discuss the therapeutic areas of
amyloidosis and Parkinson's disease and unmet medical need.
In addition to Dale Schenk, PhD, President and Chief Executive Officer,
Prothena; Gene Kinney, PhD, Chief Scientific Officer and Head of Research&Development, Prothena; Martin Koller, MD, MPH, Chief Medical Officer, Prothena;
and Kenneth Flanagan, PhD, Senior Scientist, Prothena, independent participants
include:
-- Brian Fiske, PhD, The Michael J. Fox Foundation for Parkinson's Research
-- Eliezer Masliah, MD, Neurology, University of California, San Diego
-- Pat Napoda, Amyloidosis Foundation
-- Ted Yednock, PhD, Scientific Advisor to Prothena, Former EVP and Head of
Global Research at Elan Pharmaceuticals (Athena Neurosciences)
-- Jeffrey A. Zonder, MD, Associate Professor of Oncology and Medicine and
Leader, Multiple Myeloma Program, Wayne State School of Medicine and
Karmanos Cancer Institute
About Prothena
Prothena Corporation plc. is a clinical stage biotechnology company focused on
the discovery, development and commercialization of novel antibodies for the
potential treatment of a broad range of diseases that involve protein
misfolding and cell adhesion, particularly on the discovery, development and
commercialization of potential therapeutic monoclonal antibodies directed
specifically to disease-causing proteins. These potential therapies have a
broad range of indications, including AL and AA forms of amyloidosis (NEOD001),
Parkinson's disease and related synucleinopathies (PRX002), and novel cell
adhesion targets involved in inflammatory disease and metastatic cancers
(PRX003). For more information, please visit www.prothena.com.
Investors: Tran Nguyen, CFO
650-837-8535, IR(at)prothena.com
Media: Anita Kawatra
646-256-5116, anita.kawatra(at)prothena.com
News Source: NASDAQ OMX
28.10.2013 Dissemination of a Corporate News, transmitted by DGAP -
a company of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Prothena Corporation
Ireland
Phone:
Fax:
E-mail:
Internet:
ISIN: IE00B91XRN20
WKN:
End of Announcement DGAP News-Service
---------------------------------------------------------------------------
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: EquityStory
" alt="Inca One Completes First Tranche Of Private Placement
Datum: 28.10.2013 - 14:06 Uhr
Sprache: Deutsch
News-ID 309885
Anzahl Zeichen: 7772
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 265 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DGAP-News: Prothena Announces Research and Development Day and Webcast"
steht unter der journalistisch-redaktionellen Verantwortung von
Prothena Corporation (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
